Health Care Equipment

CytoSorbents

CytoSorbents released FY2026 Q1 earnings on May 13 After-Market (EST), actual revenue USD 8.864 M (forecast USD 9.363 M), actual EPS USD -0.0817 (forecast USD -0.055)

CytoSorbents to Release FY2026 Q1 Earnings on May 13 After-Market EST, Forecast Revenue USD 9.363M, EPS USD -0.055

CytoSorbents released FY2025 Q4 earnings on March 25 After-Market EST: Actual Revenue USD 9.234 M (Forecast USD 9.215 M), Actual EPS USD -0.0875 (Forecast USD -0.05)

CytoSorbents released FY2025 annual earnings on March 25 After-Market EST, actual revenue USD 37.06 M (forecast USD 37.07 M), actual EPS USD -0.1317 (forecast USD -0.1666)

CytoSorbents to release FY2025 Q4 earnings on March 11 After-Market EST, forecast revenue USD 9.215 M, EPS USD -0.05

CytoSorbents released FY2025 9 Months earnings on November 13 After-Market (EST), actual revenue USD 27.83 M, actual EPS USD -0.0448

CytoSorbents released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 9.485 M (forecast USD 10.02 M), actual EPS USD -0.0505 (forecast USD -0.0466)

CytoSorbents to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast Revenue USD 10.02 M, EPS USD -0.0466

CytoSorbents released FY2025 Semi-Annual Earnings on August 7 After-Market EST, Actual Revenue: USD 18.34 M, Actual EPS: USD 0.0076

CytoSorbents released FY2025 Q2 earnings on August 7 After-Market (EST), actual revenue USD 9.617 M (forecast USD 9.222 M), actual EPS USD 0.0299 (forecast USD -0.0566)

CytoSorbents to Release FY2025 Q2 Earnings on August 7 After-Market (EST), Forecast Revenue USD 9.222 M, EPS USD -0.0566

CytoSorbents DrugSorb™-ATR Device Under FDA Appeal Hearing, Rejected in Canada

CytoSorbents appeals FDA's De Novo denial of DrugSorb™-ATR device

CytoSorbents Participates in Jefferies Global Healthcare Conference

CytoSorbents Treatment Significantly Reduces Bleeding and Transfusion Need in CABG Patients

CytoSorbents released FY2025 Q1 earnings on May 14 After-Market EST: Actual Revenue USD 8.727 M (Forecast USD 9.007 M), Actual EPS USD -0.0243 (Forecast USD -0.07)

CytoSorbents Reports Q1 Earnings and Raises Capital

Cytosorbents Corp Reports Loss Of 7 Cents Per Share In Q1

Cytosorbents to Release Q1 2025 Earnings Report

CytoSorbents to release FY2025 Q1 earnings on May 14 After-Market EST, forecast revenue USD 9.007 M, EPS USD -0.07

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

CTSO

CytoSorbents (NASDAQ:CTSO) reported a 2% year-over-year revenue growth to $8.9 million for Q1 2026, despite geopolitical disruptions. The company is focusing on international expansion of its Cytosorb business and is progressing towards FDA approval for DrugSorb ATR. Operational improvements led to a 22% reduction in operating loss, with a goal of achieving operating cash flow break-even in the second half of 2026. Management emphasized the growing value of Cytosorb therapy and ongoing efforts to optimize treatment protocols and expand the sales force.

benzinga_article

Transcript: CytoSorbents Q1 2026 Earnings Conference Call

Earnings Watch

CytoSorbents | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 8.864 M

CytoSorbents | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 8.864 M

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CTSO Stock News

StockTitan

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CTSO Stock News

CTSO (Cytosorbents Corporation) is set to announce its Q1'26 results on May 05, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q1'26, revenue estimate is 9.40 million USD with EPS (earnings per share) anticipated at (0.05) USD. Learn more details at .Revenue & EPS values are provided in USDQ1'25Q2'25Q3'25Q4'25Q1'26Revenue Reported8.73 M9.62 M9.48 M9.23 M—Revenue Estimate9.21 M9.40 M10.40 M9.78 M9.40 MRevenue Surprise-5.25%+2.29%-8.80%-5.58%EPS Reported(0.02) 0.03(0.04)(0.09) EPS Estimate(0.07)(0.05)(0.04)(0.06)(0.05) EPS Surprise+69.23%+160.00%+0.00%-63.64%DisclaimerSelect reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

TradingView

Factset Research

CTSO Q1'26 Earnings: EPS estimate is (0.05) USD

CytoSorbents Corporation has received a 180-day extension from Nasdaq until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing. The company plans to monitor its share price closely and may consider a reverse stock split. Currently, the stock is rated as a Hold with a price target of $0.54, reflecting concerns over financial quality and regulatory risks. CytoSorbents focuses on blood purification therapies in critical care and cardiac surgery markets.

Tip Ranks

CytoSorbents Receives Nasdaq Extension to Regain Compliance

Cytosorbents reported fiscal 2025 revenue of $37.1 million, a 4.1% increase from 2024, with a narrowed net loss of $8.2 million compared to $20.7 million the previous year. Gross profit rose to $26.5 million, achieving a 71.5% margin. The company is focusing on cost reductions and operational realignment to reach cash-flow break-even by the second half of 2026. Key initiatives include a 10% workforce reduction and a strategic shift in its German commercial team to enhance sales performance.

Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed

CytoSorbents | 10-K: FY2025 Revenue Misses Estimate at USD 37.06 M

CytoSorbents(CTSO.US)

Transcript: CytoSorbents Q1 2026 Earnings Conference Call

CytoSorbents | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 8.864 M

CytoSorbents | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 8.864 M

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CTSO Stock News

CTSO Q1'26 Earnings: EPS estimate is (0.05) USD

CytoSorbents Receives Nasdaq Extension to Regain Compliance

Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed

CytoSorbents | 10-K: FY2025 Revenue Misses Estimate at USD 37.06 M